Trinity Biotech

Trinity Biotech Retained Earnings

The Retained Earnings of Trinity Biotech (TRIB) as of Oct 17, 2026 is -116.17 M USD. In the previous year, Retained Earnings was -79.12 M USD — a change of 46.83% (lower).

Retained Earnings

-116.17 MUSD

YoY

46.83%

Last updated:

Retained Earnings of Trinity Biotech is 2025 -116.17 M USD. Retained Earnings of Trinity Biotech was 2024 -79.12 M USD. It decreases by 46.83% lower compared to the previous year.

The Trinity Biotech Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2018
24.37 M USD
Jan 1, 2019
11.51 M USD
Jan 1, 2020
10.57 M USD
Jan 1, 2021
12.56 M USD
Jan 1, 2022
-26.70 M USD
Jan 1, 2023
-48.64 M USD
Jan 1, 2024
-79.12 M USD
Jan 1, 2025
-116.17 M USD
The Trinity Biotech Retained Earnings history
YEARRetained EarningsYoY
-116.17 MUSD+46.83%
-79.12 MUSD+62.64%
-48.64 MUSD+82.22%
-26.70 MUSD-312.56%
12.56 MUSD+18.78%
10.57 MUSD-8.17%
11.51 MUSD-52.75%
24.37 MUSD-47.21%
46.16 MUSD-50.37%
93.00 MUSD-53.95%
201.95 MUSD+10.13%
183.38 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech PLC is a healthcare company based in Bray, Ireland, with a focus on developing, manufacturing, and marketing medical diagnostic products. The company serves the clinical laboratory and point-of-care segments of the diagnostic market. Trinity Biotech employs 579 full-time staff and has been publicly traded since its IPO on October 21, 1992. Its products are designed to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company operates through two geographic segments: the Americas and Rest of World. Product categories include point-of-care diagnostics, emergency medicine diagnostics, clinical laboratory reagents, and blood bank screening. The company's point-of-care brands are Uni-Gold and Recombigen, while its emergency medicine diagnostics cover acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. Trinity Biotech supplies the clinical laboratory market with reagent products and other solutions through its clinical chemistry business. The blood bank screening division manufactures products to screen donated blood for transfusion-transmissible infections. The company's website is www.trinitybiotech.com. Trinity Biotech PLC is listed on the stock market under the ticker TRIB and ISIN US8964385046. The company's headquarters are located in Bray, Wicklow, Ireland. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Retained Earnings of Trinity Biotech is -116.17 M USD in 2025.

Retained Earnings of Trinity Biotech changed from -79.12 M USD to -116.17 M USD, representing a 46.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Trinity Biotech

All Key Metrics — Trinity Biotech